Relmada Therapeutics Inc. (RLMD)
0.26
0.00 (0.00%)
At close: Mar 03, 2025, 3:59 PM
0.24
-5.22%
After-hours: Mar 03, 2025, 06:03 PM EST
Relmada Therapeutics Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 5.13K | 7.94K |
| Cost of Revenue | n/a | n/a | 1.26K | 3.75K | n/a | 4.87K | 2.63K | 85.27K | 54.82K | 9.26K | 4.04K | 5.8K |
| Gross Profit | n/a | n/a | -1.26K | -3.75K | n/a | -4.87K | -2.63K | -85.27K | -54.82K | -9.26K | 1.09K | 2.14K |
| Operating Income | -103.7M | -161.25M | -125.7M | -60.84M | -15.11M | -12.73M | -6.92M | -7.22M | -16.22M | -17.1M | -45.02K | -12.05K |
| Interest Income | n/a | 2.66M | 1.2M | 1.4M | 104.11 | -761.04K | n/a | n/a | 1.75K | 10.88K | n/a | n/a |
| Pretax Income | -98.79M | -157.04M | -125.75M | -59.46M | -15.01M | -17.32M | -8.96M | -6.29M | -2.97M | -20.8M | -45.02K | -12.05K |
| Net Income | -98.79M | -157.04M | -125.75M | -59.46M | -15.01M | -17.32M | -8.96M | -6.29M | -2.97M | -20.8M | -45.02K | -12.05K |
| Selling & General & Admin | 48.89M | 47.93M | 35.08M | 24.87M | 7.25M | 5.7M | 3.97M | 5.93M | 10.01M | 9.23M | 46.11K | 13.82K |
| Research & Development | 54.81M | 113.32M | 90.62M | 35.97M | 7.86M | 7.02M | 2.94M | 1.29M | 6.21M | 7.87M | 5.38M | n/a |
| Other Expenses | -293 | 6.35M | n/a | n/a | n/a | n/a | 2.35K | 216.21K | 130.27K | n/a | n/a | n/a |
| Operating Expenses | 103.7M | 161.25M | 125.7M | 60.84M | 15.11M | 12.73M | 6.92M | 7.22M | 16.22M | 17.1M | 46.11K | 13.82K |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 1.34M | 550.00 | n/a | 4.92K | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.03K | 4.73K |
| Cost & Expenses | 103.7M | 161.25M | 125.7M | 60.84M | 15.11M | 12.73M | 6.92M | 7.22M | 16.22M | 17.1M | 50.14K | 19.62K |
| Income Tax | n/a | -2.66M | 48.32K | -1.38M | -1 | 4.59M | 2.05M | -716.1K | -13.11M | 3.7M | -9.58M | -377 |
| Shares Outstanding (Basic) | 30.1M | 29.63M | 17.55M | 15.59M | 9.23M | 6.31M | 3.14M | 3.02M | 2.9M | 2.49M | 1.43M | 1.43M |
| Shares Outstanding (Diluted) | 30.1M | 29.63M | 17.55M | 15.59M | 9.23M | 6.31M | 3.14M | 3.02M | 2.9M | 2.49M | 1.43M | 1.43M |
| EPS (Basic) | -3.28 | -5.3 | -7.16 | -3.81 | -1.63 | -2.74 | -2.86 | -2.08 | -1.03 | -8.37 | -0.03 | -0.01 |
| EPS (Diluted) | -3.28 | -5.3 | -7.16 | -3.81 | -1.63 | -2.74 | -2.86 | -2.08 | -1.03 | -8.37 | -0.03 | -0.01 |
| EBITDA | 4.91M | -157.04M | -125.75M | -59.45M | -15.1M | -16.55M | -6.91M | -6.92M | -16.03M | -17.09M | -45.02K | -11.68K |
| Depreciation & Amortization | 103.7M | 2K | 1.26K | 3.75K | 4.36K | 4.87K | 2.63K | 85.27K | 54.82K | 9.26K | 250.00 | 754.00 |